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 Insulin-stimulated glucose uptake requires the activation of the nonmuscle motor 
protein myosin II.  Our previous studies using pharmacological inhibitors suggest that 
insulin signaling results in the phosphorylation of myosin IIA during insulin-stimulated 
glucose uptake in 3T3-L1 adipocytes.  Since pharmacological inhibitors are not specific, 
we wanted to use a siRNA approach to complement our previous studies.   In this report 
we demonstrate that knockdown of myosin IIA using a myosin IIA-specific siRNA 
resulted in impaired insulin-stimulated glucose uptake.  To delineate the signaling 
pathway involved we asked if siRNA specific to myosin light chain kinase (MLCK), an 
upstream regulator of myosin IIA, would have the same effect.   While we did not 
observe a reduction in MLCK or impairment of insulin-stimulated glucose uptake, we 
were able to observe that MLCK is phosphorylated upon insulin stimulation suggesting a 
role for MLCK in insulin-stimulated glucose uptake.    Next, we used siRNA specific to 
extracellular-signal regulated kinase 2 (ERK2) to establish a role for this kinase in 
insulin-stimulated glucose uptake.   Our results revealed that knockdown of ERK2 
resulted in reduced phosphorylation of MLCK.  Knockdown of ERK2 also impaired 
insulin-stimulated glucose uptake in 3T3-L1 adipocytes.  Lastly, we used siRNA specific 
to the calcium/calmodulin kinase II delta isoform to explore its role as a potential 
upstream activator of ERK2.  Only a slight decrease in CaMKIIδ expression was 
achieved, but this did not result in a significant change in insulin-stimulated glucose 
uptake.   Taken together, our results suggest that myosin IIA is involved in insulin-
 
stimulated glucose uptake and that it is regulated via MLCK phosphorylation by ERK2 
resulting in regulation of glucose uptake upon insulin stimulation in 3T3-L1 adipocytes.   
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CHAPTER  I 
INTRODUCTION 
 
Diabetes mellitus is a metabolic disorder that is characterized by a malfunction in 
glucose homeostasis causing blood glucose levels to be dangerously elevated.  According 
to the International Diabetes Foundation, approximately 246 million people worldwide 
were diagnosed with diabetes in 2006 with ninety-five percent of those individuals 
having type II diabetes.  Type II diabetes is characterized by insulin resistance and 
obesity.   Insulin resistance results when chronic high levels of glucose causes a failure of 
primarily white adipose tissue and skeletal muscle to respond to insulin due to chronic 
high levels of glucose.  Due to this insulin resistance, these tissues no longer effectively 
clear the blood of excess glucose.  As developing countries continue to be influenced by a 
westernized lifestyle of high fat, high carbohydrate meals, and sedentary habits, it is 
predicted that the number of type II diabetics will continue to rise to epidemic 
proportions.  Understanding the pathways involved in glucose homeostasis will provide 
more targets for pharmacological approaches to treating type II diabetes.  In this context, 
the insulin signaling pathway and the molecular mechanisms underlying glucose uptake 
by adipocytes is a major field of interest.  
Insulin Signaling 
Increases in plasma blood glucose levels signal the β cells of the pancreas to 
release insulin which binds to receptors located on the surface of adipocytes and skeletal 
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muscle cells. Insulin binds to a tyrosine kinase receptor on the surface invoking 
autophosphorylation of its cytosolic tyrosine kinase domains.  With these tyrosine kinase 
domains activated, the insulin receptor can subsequently phosphorylate various docking 
proteins in the signal transduction pathway.  The insulin receptor substrate (IRS) family 
is the most common of these docking proteins.  IRS phosphorylates other proteins such as 
phosphatidylinositol 3-kinase (PI3K) leading to the activation of Akt (also known as 
PKB) which has been linked to numerous downstream events such as vesicle 
translocation, gene transcription, and cytoskeletal remodeling (2-6, 10).  Not all the 
potential downstream targets of Akt, however, have yet been identified.   
One event triggered by insulin signaling in the adipocyte is the translocation of 
the internal stores of the facilitative glucose transporter, GLUT4, to the plasma 
membrane.  Under basal conditions, GLUT4 is primarily localized in vesicles around the 
nucleus and these vesicles respond to insulin signaling by translocating and fusing with 
the plasma membrane resulting in increased glucose uptake (7) (Fig. 1)
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Figure 1. Representation of the insulin signaling pathway for glucose uptake in 
adipocytes. 
 
The Role of the Cytoskeleton in Vesicle Trafficking 
The cytoskeleton plays a necessary role in vesicle trafficking as well as in the 
docking and fusion of GLUT4 vesicles at the plasma membrane.    In mature, 
differentiated adipocytes, filamentous (F) actin lines the inner surface of the plasma 
membrane.  This cortical actin has been suggested to play a regulatory role in the 
processes of vesicle fusion and exocytosis by acting as a barrier to docking and fusion 
sites at the plasma membrane (3, 4, and 10).  The insulin signaling pathway has been 
shown to induce the reorganization of this cytoskeletal barrier which is vital to GLUT4 
vesicle fusion and thus GLUT4-mediated glucose uptake (2).  The regulatory 
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mechanisms guiding this reorganization that have become a recent target of research.  
Motor proteins are thought to be a link in this regulation by allowing the actin filaments 
to contract.  Recent studies have postulated that non-muscle myosin II is required for the 
cortical actin to reorganize and allow GLUT4 access to the plasma membrane to facilitate 
glucose uptake in the adipocyte (8, 14).  Adipocytes have previously been shown to 
express two isoforms of non-muscle myosin II:  myosin IIA and myosin IIB (8). 
Myosin II 
Non-muscle myosin II is a hexameric protein made up of two heavy chains, two 
regulatory light chains (RLC), and two essential light chains (ELC) (Fig. 2).  The two 
heavy chains are structurally comprised of a globular head, a α-helical coiled coil middle 
region, and a non-helical tail region.  The globular head region is the site of ATP binding 
and also the actin binding regions.  Phosphorylation of serine 19 on the RLC induces the 
activity of the ATPase and hence contraction of the actin filaments (13).
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Figure 2.  Representation of Myosin II Structure.  Myosin II is composed of 2 heavy 
chains with globular heads (white), 2 regulatory light chains (black), and 2 essential light 
chains (gray) (13). 
 
The two isoforms of myosin II in adipocytes interact with heavy chains encoded 
by different genes.  The localization of the myosin II isoforms have been found to be 
species-and cell type-specific suggesting that the isoforms play distinct regulatory roles 
depending on cell type (9,12,25-27).  In bovine arterial endothelial cells the myosin IIA 
and IIB isoforms have distinct spatial arrangements within the cell, which are altered 
when the cell undergoes migration, suggesting the localization patterns are indicative of 
specialized functions in the these cells (12).  siRNA has been used to show that the 
localizations as well as the functions of the myosin II isoforms may differ depending on 
cell type (11, 26, 27).
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Possible Role for Myosin II in Glucose Uptake in Adipocytes 
In 3T3-L1 adipocytes, myosin IIA and IIB have different localization patterns 
under basal and insulin-stimulated conditions suggestive of diverse roles (8).  Confocal 
microscopy has revealed that myosin IIB is localized at the cell cortex under basal 
conditions and does not appear to change its localization upon insulin stimulation.  
Myosin IIA, however, has a perinuclear localization under basal conditions and then 
translocates to the cortex upon insulin stimulation (8). Interestingly, this is similar to the 
localization pattern of GLUT4 vesicles (4) and suggests a possible role for myosin IIA in 
GLUT4 vesicle trafficking (8).  Treatment of adipocytes with blebbistatin (a chemical 
inhibitor that binds to the motor domain of non-muscle myosin II resulting in inhibition 
of ATPase activity) resulted in significant impairment of insulin stimulated glucose 
uptake without affecting Akt phosphorylation or the translocation of GLUT4 vesicles (8).    
This suggests that myosin IIA may play an important role in glucose uptake by affecting 
the end process of GLUT4 vesicle fusion with the plasma membrane (8).  
Although myosin IIA and GLUT4 translocate independently to the plasma 
membrane, myosin IIA activity is necessary for the fusion of GLUT4 vesicles to the 
membrane and also for the intrinsic activity of GLUT4 to allow the process of glucose 
uptake (14).  Using confocal microscopy, both GLUT4 and myosin IIA were shown to 
co-localize at the plasma membrane only after insulin stimulation, consistent with an 
interactive role in the process of glucose uptake in the adipocyte.  In addition, myosin IIA 
co-immunoprecipitates with GLUT4 only after insulin stimulation in adipocytes (14).
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In our lab we have recently used chemical inhibitors to prevent the activation of 
myosin II, revealing its potential role in the glucose uptake process in adipocytes (14).   
Chemical inhibitors such as blebbistatin inhibit myosin II activity but this inhibition is 
not selective for the individual isoforms.  Since adipocytes express both myosin IIA and 
IIB, it is important to distinguish the roles that the two isoforms play in insulin-stimulated 
glucose uptake in 3T3-L1 adipocytes.   My research used the technique of small 
interfering RNA (siRNA) for post-transcriptional gene silencing (PTGS) to specifically 
and effectively knockdown the expression of the myosin II isoforms.     I hypothesized 
that myosin IIA is necessary for GLUT4-mediated glucose uptake upon insulin 
stimulation in adipocytes, while myosin IIB is not a major factor in insulin stimulated 
glucose uptake.   
Possible Role for MLCK in Insulin-stimulated Glucose Uptake 
With evidence of a critical role for myosin IIA in glucose uptake, the mechanisms 
regulating the activation of this protein are critical.   Myosin II is regulated by 
phosphorylation of the RLC, and MLCK is known to phosphorylate the RLC. 
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Figure 3.  Representation of sequence motifs of the long and short isoforms of smMLCK.  The long 220kDa 
isoform has 2 additional D(V/F)XXR repeats and 6 Ig motifs (30). 
 
MLCK is a calcium/calmodulin-dependent (CaM) kinase most notably known for 
its role in activating myosin II to effect smooth muscle contraction.  There are three 
known human genes that code for MLCK.  Mylk2 and mylk3 code selectively for skeletal 
and cardiac tissue respectively.  Mylk1, also known as the smooth muscle MLCK, is 
expressed in all adult tissues (36).   Mylk1 encodes 3 different protein products from one 
open reading frame.  The 220 kDa isoform is also known as the non-muscle MLCK.   It 
contains the full sequence of the other two proteins plus an additional amino-terminal tail 
region that is associated with extended protein-protein interactions to actin filaments.  
The other two proteins are the 108/130 kDa and the 17 kDa kinase related protein (KRP) 
also known as telokin (31).   
While several kinases are known to phosphorylate the RLC of Myosin II, only 
inhibition of MLCK has been shown to result in impaired phosphorylation of the RLC 
upon insulin stimulation. Interestingly, RLC is also the only known substrate for MLCK 
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(8, 11-14).  Rho kinase has also been found to phosphorylate the RLC of myosin II.  
Previous studies have suggested that Rho kinase activity is limited to the interior of the 
cell and MLCK acts along stress fibers in the cell and along the periphery (30) suggesting 
a role for MLCK in an exocytic process.   Previous studies in our lab revealed that 
chemical inhibition of MLCK but not Rho kinase significantly impaired insulin-
stimulated glucose uptake (14).   
Our lab has also shown that it is specifically MLCK that phosphorylates myosin 
IIA as a result of insulin signaling.  Our lab was able to show that the MLCK inhibitor 
ML-7 [1-(5-iodonaphthalen-1-sulfonyl) homopiperazine] prevented the phosphorylation 
of the RLC associated with myosin IIA, impairing its translocation to the membrane.     
The chemical inhibition of myosin IIA with blebbistatin (an inhibitor of myosin II 
ATPase activity) and more specifically the inhibition of MLCK with ML-7 dramatically 
decreased the level of GLUT4 vesicle fusion at the membrane in the presence of insulin 
and resulted in a significant decrease in glucose uptake in adipocytes (14). 
In order to determine the role of MLCK in the activation of myosin IIA, I used 
siRNA to knockdown expression of MLCK.  I hypothesized that as a result of insulin 
signaling, MLCK phosphorylates the RLC of myosin IIA and results in GLUT4-mediated 
glucose uptake in adipocytes. 
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Possible Role for ERK2 in Insulin-stimulated Glucose Uptake 
While insulin is known to activate the PI3K pathway, it also stimulates many 
other intracellular pathways such as the Mitogen-Activated Protein Kinase (MAPK) 
pathway. One of the leading targets of this transduction pathway is the extracellular-
signal regulated kinases 1 and 2(ERK1/ERK2) though activation of the RAS, RAF, MEK 
cascade.   MEK is an immediate upstream activator of ERK1/2.   Previous studies have 
shown that in the presence of a constitutively active MEK (MAPKK) there is an increase 
in phosphorylation of ERK1/2, MLCK, and RLC (42).  ERK1/2 has been shown to 
directly phosphorylate MLCK initiating its activation (42).  It was also determined that 
ERK2 in the absence of MLCK expression was not sufficient to phosphorylate the RLC 
of myosin II (42). The MEK inhibitor, U-0126, not only decreases phosphorylation of 
ERK1/2 but also impairs insulin-stimulated glucose uptake in adipocytes giving further 
evidence of the MAPK pathway in glucose uptake (28).  
Another substrate for ERK1/2 is the insulin receptor substrate-1 (IRS-1) which is 
upstream of PI3K in the insulin signaling pathway.  Phosphorylation on serine 612 of 
IRS-1 by ERK inhibits further insulin signaling by providing negative feedback for this 
pathway mitigating chronic activation by insulin (39). Since their discovery, the two 
ERKs were thought to have redundant functions due to their sequence similarity and co-
expression in a myriad of tissues.  ERK1 and ERK2 knockout mice, however, have 
distinctly different phenotypes.  ERK2 knockout mice die as embryos while ERK1 
knockout mice have only slight developmental defects (40).  In each knockout line, 
expression of the remaining ERK does not increase, suggesting these proteins are not 
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interchangeable (40).   A study using short hairpin RNA in mouse embryonic fibroblasts 
to knockdown expression of ERK1 found that these cells appeared to increase  
proliferation while those with a decrease in ERK2 expression had a decrease in 
proliferation (46).   In addition, a study using mouse C2C12 muscle cells found that it was 
specifically ERK2  levels that increased upon leptin stimulation and not ERK1 (50).   As 
well, the inhibition of ERK2 using the MEK inhibitor, PD98059, resulted  in a reduction 
of insulin-stimulated glucose uptake as well as a reduction in GLUT4 recruitment to the 
plasma membrane (50). These results suggest that it is ERK2 that plays a major role in 
glucose uptake. 
I hypothesized that it is specifically ERK2 that plays a necessary role in insulin-
stimulated glucose uptake by the activation of myosin IIA via the phosphorylation of 
MLCK.  I predicted that cells deficient in ERK2 protein would have impaired insulin-
stimulated glucose uptake. 
Possible Link Between CaMKIIdelta , MLCK, and ERK1/2 Regulation 
CaM kinase II has also been suggested to have a regulatory role in the activation 
of MLCK.   In vitro studies have shown MLCK to be phosphorylated by CaMKII (37).   
CamKII is an oligomeric protein comprised from 4 different genes that code for 
individual subunits-α, β, γ, and δ.  The α and β subunits are primarily expressed in 
neuronal tissue and the γ and δ subunits are expressed in a variety of tissues (35).  The 
holoenzyme can be made up of monomers of the same or differing isoforms allowing for 
a large range of possible compositions (49).  CaMKII is a serine/theonine kinase that 
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belongs to the same family of Ca2+/CaM dependent kinases as MLCK.     CaMKII has 
been found to be activated by the binding of calcium/calmodulin initiating its 
autophosphorylation.  Due to CaMKII’s stacked structure, there is constitutive activation 
though this autophosphorylation of the kinase long after transient levels of calcium have 
decreased.  It is this calcium-independent state that has led some researchers to suggest a 
more permissive role in insulin-stimulated glucose uptake than a regulatory role (35).  
Studies using chemical inhibitors of CaMKII such as KN62 as well as other 
studies using calmodulin inhibitors have implicated a possible role for CaMKII in 
insulin-stimulated glucose uptake.  A recent study using a purine analog inhibitor to 
CaMKII as well as cells expressing a mutant form of CaMKII revealed a significant 
decrease in insulin-stimulated glucose uptake (35).  This inhibitor did not have a negative 
effect on the phosphorylation status of IR, IRS-1, p38MAPK, or Akt indicating a 
necessary role for CaMKII downstream of Akt activation (35).   While the insulin 
signaling events preceding Akt phosphorylation are well defined, the substrates for Akt 
are still unknown.   
CaMKII has also been linked to the regulation of ERK1/2 by way of its activation 
of RAF-1 upstream of MEK and ERK activation.  It has recently been shown that 
CaMKII inhibition resulted in decreased glucose uptake (39).  However, this study was 
performed for a 30 minute time point only, and it has been suggested that a longer time 
course study might have found that inhibition of CaMKII would result in an increased 
level of glucose uptake.   It has been proposed that CaMKII plays a central role in 
13 
regulating the signaling events of ERK1/2.  It is possible that in response to a constitutive 
signal CaMKII will actually inhibit glucose uptake by way of activation of ERK1/2 
negative feedback loop (39). 
With this in mind the siRNA technique was again used to down-regulate 
expression of CaMKIIδ to determine its role in regulating myosin IIA activation and 
insulin-stimulated glucose uptake.   I hypothesized that inhibition of CaMKIIδ expression 
would inhibit myosin IIA phosphorylation by way of decreased MLCK phosphorylation 
and thus insulin-stimulated glucose uptake in 3T3-L1 adipocytes. 
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CHAPTER II 
MATERIALS AND METHODS 
 
Materials 
The following materials were obtained for this study.  Cell culture media 
Dulbecco’s Modified Eagle Medium High Glucose 1X Cat # 11995 was purchased from 
Gibco.  Cell culture 15 cm plates were purchased from Greiner Bio-One Cat # 662160.   
Electroporation Gene Pulser cuvettes with a 0.4 cm electrode gap were obtained from 
BioRad Cat # 165-2088.   Insulin was obtained from bovine pancreas and purchased 
through Sigma-Aldrich St.Louis,MO Cat # 15500-1G 016K1248, as well as 
dexamethasone , 3-isobutyl 1-methyl-xanthine (MIX) Sigma Cat# I5879, and Anti-Rabbit 
Secondary antibody from Sigma Cat # A 6154.   Myosin IIA and IIB antibody was 
purchased from Covance Cat # PRB-440-P and from Cat # PRB-445-P respectively.   
The following antibodies were obtained through Cell Signaling: Actin Cat # 4968, 
ERK1/2 Cat # 9102, and P-ERK Cat # 9101S.    MLCK and GLUT4 antibody was 
obtained from Santa Cruz Cat # 22223 and #1608 respectively.    P-MLCK antibody was 
purchased from Invitrogen Cat # 441085G.   CaMKIIdelta antibody was received as a 
generous gift from Dr. Singer’s lab from Albany Medical College, New York.  
Cell Culture 
3T3-L1 fibroblasts were grown to confluency and then induced to differentiate 
using 10% Fetal Bovine Serum (FBS) / Dulbecco’s Modified Eagle Media (DMEM) with 
the  addition of 0.52 mM 3-isobutyl 1-methyl-xanthine (MIX), 1.7 µM insulin, and 1 µM 
15 
dexamethasone (DEX) on Day 0 (23).  On Day 2, the media was changed to 
10%FBS/DMEM plus 0.425 µM Insulin.  Every two days thereafter the media was 
replaced with DMEM containing 10% FBS (23, 24). 
siRNA Duplexes 
The siRNA was purchased from Dharmacon, Inc. using ON-TARGET plus Smart 
POOL (see Appendix A for target sequences). 
Electroporation 
Day 8 3T3-L1 adipocytes were washed with a 1X Phosphate Buffered Saline 
(PBS) and solubilized using 0.5% trypsin-EDTA.  After a 6 min incubation at 37°C and 
5% CO2, cells were resuspended in 10% FBS/DMEM and centrifuged for 5 min at 100 X 
g.  The supernatant was removed and the cells were resuspended in 1 X PBS and 
centrifuged for 5 min at 100 X g twice.  Finally, the cell pellet was resuspended in 1 ml 1 
X PBS per 15 cm plate used.  Cuvettes (4 mm gap) containing 1 nmol of the siRNA 
(water, Myosin IIA, Myosin IIB, Scramble, MLCK, CaMKIIδ , or ERK2) were prepared 
and placed on ice.  A volume of 500 µl containing 2.5 x 10
6
 cells along with the 1 nmol 
of siRNA was electroporated  at 0.18 kV and 975 microfarads using a Bio-Rad Gene 
Pulser II.  Immediately after electroporation, cells were re-suspended in 8.5 ml of 
10%FBS/DMEM and the upper layer of lipid debris was removed using a pipette tip.  
After a 10 minute incubation period at room temperature, cells were re-plated onto multi-
well plates.   After 24 h, media was replaced with 10% FBS/DMEM (21, 22).
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Glucose Uptake Assay 
Electroporated 3T3-L1 adipocytes were re-plated onto 6-well plates and given a 
48 h recovery period.   The cells were then serum starved for a period of 4 h followed by 
2 washes with 37°C  Krebs Ringer Phosphate Buffer (KRP) pH7.4  containing 1.65 mM 
CaCl2, 1.25 mM MgSO4, 4.69 mM KCl, 5 mM Na2HPO4, and 130 mM NaCl.  The cells 
were incubated in 950 µL of KRP/well for 10 min in a shaking water bath at 37°C.  The 
designated treatment wells underwent insulin stimulation for 20 min with the application 
of 10 µl of insulin per well for a total concentration of 100 nM followed by the addition 
of 50 µl of a Glucose Solution containing KRP, 0.5 M glucose, and  
14
C-deoxy-glucose.  
Total exposure of the cells to 
14
C-deoxy-glucose was 10 min.   Wells were washed twice 
with 1 X PBS at 4°C and lysed with a 0.5 M NaOH/0.1% SDS solution and then counted.     
The quantity of 
14
C-2-deoxy-glucose uptake was assayed as disintegrations per min per 
mg protein and normalized to 1 representing basal levels (23). 
Immunoblot Analysis 
Electroporated 3T3-L1 adipocytes were re-plated onto 6 cm plates and given a 48-
72 h recovery period.   The cells then underwent a 4 h serum starvation period followed 
by 2 washes with KRP at 37°C.  The wells designated for insulin treatment received 1 
µl/1 ml KRP per well for a final insulin concentration of 100 nM and incubated at 37°C 
and 5% CO2 for 20 min  Cells were washed with 1 X PBS and then solubilized in a lysis 
buffer ( 25 mM Hepes, pH 7.4, 100 mM NaCl, 5 mM NaF, 1 mM EDTA, 1 mM NaPPi, 
2% Glycerol, and 1% NP-40 ) containing10 X Phosphatase cocktail (1:10) and protease 
inhibitors (1:100).   The proteins were gently rocked for 20 min then centrifuged for 20 
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min at 4°C. The supernatant was collected and protein concentration was determined 
using the BSA Protein Concentration Standard Curve Spectrophotometer software.  
Samples were mixed with a 5 X Laemmli buffer and boiled for 5-10 min at 95°C then 
separated by 10% SDS-PAGE.  The proteins were transferred to an Immobilon filter and 
then incubated for an h in a blocking solution of 1 X TTBS and 4% BSA.  The primary 
antibody (1:1000) was diluted in this blocking solution and the filter was incubated at 
4°C overnight while gently rocking.  After 3 washes with 1 X TTBS, the filters were 
incubated in a solution containing the secondary antibody (1:2000) and 1 X TTBS for 45 
min at room temperature.   Filters underwent 3 washes with 1 X TTBS and were 
developed using the enhanced chemiluminescent (ECL) detection kit. 
Immunofluorescence 
Coverslips were mounted onto slides using a 50% glycerol solution. The slides 
were viewed using the Olympus IX81 Motorized Inverted Confocal Microscope and 
Fluoview FV500 software. 
Optical Densitometry 
 Protein band intensity was quantified by densitometry using Quantity One 
software.  Immunoblots were probed for myosin IIA and IIB and normalized to actin 
levels. 
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CHAPTER III 
RESULTS 
 
Determination of Transfection Efficiency  
In order to optimize our electroporation protocol, we first wanted to determine 
transfection efficiency.   3T3-L1 adipocytes were electroporated with a siGLO 
transfection indicator targeting cyclophilin-B.  Cyclophilin-B, also known as 
peptidylprolyl isomerase B, is commonly expressed in most tissues and cell viability is 
unaffected by its resultant knockdown with siRNA.   These fluorescent oligonucleotides 
allow for visual assessment of transfection efficiency with the aid of confocal 
microscopy.    Mature 3T3-L1 adipocytes were electroporated with either a vehicle 
(water) or increasing concentrations of the siGLO (Figure 4).  Our results show there was 
a significant increase in transfection efficiency of the siGLO at the 500 nM concentration 
compared to the lower concentrations indicating a minimum of 500 nM for optimum 
transfection.   These results suggest that our technique of transfecting cells with siRNA 
was successful. 
Next we wanted to determine if we could impair expression of myosin IIA using 
siRNA.   Mature 3T3-L1 adipocytes were electroporated with siRNA for Myosin IIA 
using increasing concentrations.  Proteins were then collected at day 2 and 3 after 
electroporation of the siRNA to determine both the optimal concentration and the optimal 
time point for knockdown.    In order to ensure even loading of protein samples on the 
SDS-PAGE, immunoblots were probed with an antibody against actin.  As a control, 
19 
scramble oligonucleotide sequences were also electroporated at various concentrations to 
verify specificity of siRNA knockdown.  The scramble sequences have no murine gene 
target thereby providing a negative control for the study.  Consistent with a known half-
life of 72 h for myosin IIA, it was determined that optimal experimental conditions for 
decreased protein expression peaked at 72 h (Figure 5). Determining the concentration 
and time point required for optimal knockdown was critical so that we could investigate 
the effect of specific genes on glucose uptake in 3T3-L1 adipocytes.  
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Figure 4.  Determination of transfection efficiency using siRNA GLO.  Mature 3T3-
L1 adipocytes were electroporated with increasing concentrations of the transfection 
indicator siRNA Glo.  Coverslips were fixed 24hours after transfection and assessed for 
transfection efficiency using confocal microscopy. 
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Figure 5.  Reduced myosin IIA protein expression with increasing concentrations of 
siRNA.  Following electroporation with various myosin IIA siRNA concentrations, 
proteins were collected on days 2 and 3 and assayed for myosin IIA or actin protein 
levels determined by Western blot analysis.  Protein levels were normalized by 
comparison with actin levels. 
 
Knockdown of Protein Levels of the Myosin II Isoforms with siRNA Transfection  
Myosin IIA and myosin IIB have heavy chains that are encoded by isoform 
specific genes.    72 h after transfection of fully differentiated adipocytes with the target 
specific siRNA, protein levels of myosin IIA, myosin IIB, and actin were examined.  
Scramble siRNA were used as a control.  Western blots were performed to determine 
knockdown of the target protein in relation to actin.   It was determined by optical 
densitometry that protein levels of myosin IIA were reduced by ~60% and myosin IIB by 
~50% to that of either the vehicle or the scramble electroporated cells.   The cells 
electroporated with siRNA for myosin IIA did not have a decrease in myosin IIB 
expression.    However, it was also observed that the myosin IIB siRNA knocked down 
the expression of the myosin IIB as well as myosin IIA equally, suggesting a shared 
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sequence region was targeted by the siRNA instead of a region specific to myosin IIB  
(Fig. 6).    
 
 
Figure 6.  Decreased levels of myosin IIA and IIB following siRNA transfection.  
3T3-L1 adipocytes were either electroporated with vehicle (water) or with 1 nmole of 
siRNA (Scramble, MyoIIA, or MyoIIB).  After 72 h cells were serum starved for 4 h and 
then either left untreated or stimulated with insulin (100 nM) for 20 min Whole cell 
lysates were prepared, subjected to SDS-PAGE and then immunoblotted using antibodies 
against myosin IIA, myosin IIB or actin. 
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Knockdown of Myosin IIA Impairs Insulin-stimulated Glucose Uptake in 3T3-L1  
Adipocytes 
Previously, we have shown that the myosin IIA isoform is involved in insulin-
stimulated glucose uptake.  We next wanted to determine whether the knockdown of the 
myosin IIA isoform would impair insulin-stimulated glucose uptake in adipocytes.  
Glucose uptake assays were performed with [1-
14
C]-2-deoxy-D-glucose to assess the 
effect of myosin IIA and myosin IIB knockdown on glucose uptake in adipocytes.  There 
was no noticeable effect on glucose uptake under basal conditions with the knockdown of 
either myosin IIA or IIB compared to the vehicle or scramble (Figure 7).   Cells 
transfected with a vehicle (water), scrambled non-coding  sequence, or siRNA specific to 
either myosin IIA or myosin IIB were stimulated with 100 nM insulin for 20 min along 
with  [1-
14
C]-2-deoxy-D-glucose and assessed for [1-
14
C]-2-deoxy-D-glucose uptake.  
Glucose uptake was decreased by approximately 30% for myosin IIA-deficient cells as 
compared to the vehicle.  There was also a noticeable fold decrease in glucose uptake in 
cells deficient in myosin IIB, however as observed from the western blot analysis, both 
myosin IIB and myosin IIA protein levels were knocked down in the cells making these 
results less conclusive (Figure 7). 
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Figure 7.  Knockdown of Myosin IIA impaired insulin-stimulated glucose uptake.  
Mature 3T3-L1 adipocytes were electroporated with vehicle (water) or with 1 nmole of 
the target siRNA (Scramble, MyoIIA, or MyoIIB).  After 72 h cells were serum starved 
for 4 h and then either untreated (Basal) or stimulated with insulin (100 nM) for 20 min, 
followed by the addition of [1-
14
C]-2-deoxy-D-glucose (0.1µCi/well) and 5 mM glucose 
for an additional 10 min.  Cells were then lysed and glucose uptake calculated as 
disintegrations per mg protein.  
 
Insufficient Knockdown of MLCK  
We have previously shown that pharmacological inhibition of MLCK but not Rho 
kinase had an inhibitory effect on insulin-stimulated glucose uptake in 3T3-L1 
adipocytes. (14)  To further support this finding, mature adipocytes were electroporated 
with siRNA specific for MLCK.  Western blot analysis was performed to verify the 
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knockdown of MLCK.  In non-muscle cells MLCK has the molecular weight of 220kDa 
and in smooth muscle cells MLCK is 150kDa.  While I was not able to locate a band at 
either the 220 or 150 kDa sizes, a smaller band was detected.   According to product 
description for the use of the MLCK antibody and personal communication with Dr. 
Anne Bresnick of Albert Einstein College of Medicine, there is a proteolytic fragment of 
64 kDa.  Using an MLCK antibody as well as a phospho-MLCK antibody, we detected 
the 64 kDa protein breakdown product.   Our results show that MLCK knockdown was 
unsuccessful (Figure 8).  However, we observed that the phosphorylation status of 
MLCK was noticeably increased upon insulin-stimulation compared to basal conditions 
giving further evidence of a role for MLCK in insulin-stimulated glucose uptake (Figure 
8).  
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Figure 8.  No change in protein expression levels of MLCK following siRNA 
transfection.  3T3-L1 adipocytes were electroporated with siRNA (1 nmole) targeting 
either MLCK or a scrambled sequence (Scr).   After 48 h cells were serum starved for 4 h 
and then either left untreated or stimulated with insulin (100 nM) for 20 min. Whole cell 
lysates were prepared, subjected to SDS-PAGE and then immunoblotted using antibodies 
against MLCK, P-MLCK, or actin.   
 
As expected, with no apparent decrease in protein expression of MLCK, there was 
no change in insulin-stimulated glucose uptake in cells electroporated with siRNA 
specific to MLCK compared to cells electroporated with a scramble sequence of siRNA 
(Figure 12).  It is possible that a higher concentration of siRNA targeting the mRNA 
sequence for this gene is needed for sufficient knockdown.  
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Figure 9.  No effect in glucose uptake in insulin-stimulated cells subjected to MLCK 
siRNA transfection.  Adipocytes were electroporated with 1 nmole of either MLCK or a 
scrambled sequence (Scr). Adipocytes were serum starved for 4 h and then either 
untreated (Basal) or stimulated with insulin (100 nM) for 20 min.  Cells were then 
incubated in a solution containing [1-
14
C]-2-deoxy-D-glucose (0.1µCi/well) and 5 mM 
glucose for an additional 10 min.  Cells were lysed and glucose uptake calculated as 
disintegrations per mg protein. 
 
siRNA Induced Inhibition of ERK2 Expression 
ERK1 and 2 have been shown to have increased phosphorylation upon insulin 
signaling.  ERK activation has also been found to induce the phosphorylation status of 
RLC, however ERK alone was not sufficient for this role (42).  In a previous study ERK2 
specifically was found to induce phosphorylation of MLCK and that in the absence of 
MLCK ERK2 was unable to phosphorylate RLC (42).   I propose that ERK mediates the 
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phosphorylation of RLC by way of MLCK activation.  It has also been suggested that 
ERK1 and 2 have distinct cellular functions and are not redundant.  To assess the role of 
ERK2 specifically in this signal transduction pathway, I transfected adipocytes with 
siRNA targeting ERK2 and then assayed glucose uptake 48h after electroporation.  As 
determined by immunoblot analysis (Figure 10), ERK2 levels were markedly reduced 
following siRNA treatment in comparison to protein levels in cells electroporated with a 
scramble siRNA.    In addition, our results show that insulin-stimulated phosphorylation 
of MLCK was markedly reduced in cells electroporated with ERK2 siRNA compared to 
that of cells electroporated with a scramble sequence.   This suggests that ERK2 is an 
upstream activator of MLCK. 
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Figure 10.  siRNA treatment effectively decreased protein levels of ERK2.  3T3-L1 
adipocytes were electroporated with siRNA (1 nmole) targeting either ERK2 or a 
scrambled sequence (Scr). After 48 h adipocytes were serum starved for 4 h and then 
either left untreated or stimulated with insulin (100 nM) for 20 min. Whole cell lysates 
were prepared, subjected to SDS-PAGE and then immunoblotted using antibodies against 
either  an ERK antibody (that detects both p44 ERK1 and p42 ERK2), P-ERK, P-MLCK, 
or actin.
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Knockdown of ERK2 Impairs Insulin-stimulated Glucose Uptake in Adipocytes  
Next, we wanted to determine the impact the reduced level of ERK2 would have 
on insulin-stimulated glucose uptake in the adipocytes.   Figure 12 reveals no noticeable 
difference in the basal levels of glucose uptake into the cells with reduced levels of ERK2 
compared to the control.  However, under insulin-stimulated conditions, ERK2 deficient 
cells have a 20% decrease in glucose uptake compared to scramble.  These results are 
suggestive of a role for ERK2 in insulin-stimulated glucose uptake in the adipocyte.  
  
 
Figure 11.  ERK 2 deficient cells have impaired glucose uptake in insulin-stimulated 
cells.  Adipocytes were electroporated with 1 nmole of either ERK2 or a scrambled 
sequence (Scr). Adipocytes were serum starved for 4 h and then either untreated (Basal) 
or stimulated with insulin (100 nM) for 20 min.  Cells were then incubated in a solution 
containing [1-
14
C]-2-deoxy-D-glucose (0.1µCi/well) and 5 mM glucose for an additional 
10 min.  Cells were lysed and glucose uptake calculated as disintegrations per mg protein.
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Knockdown of CaMKIIδ  mRNA Expression 
We also examined the role of CaMKIIδ  in insulin-stimulated glucose uptake in 
3T3-L1 adipocytes.   Inhibitor studies, using the CaMKII inhibitor, KN62, have 
implicated a role for CaMKII in insulin-stimulated glucose transport.   CaMKII has 
multiples substrates, and it has been suggested to play a role in the regulation of MLCK 
and ERK. With this in mind, we next wanted to explore a role for CaMKIIδ  as a 
potential upstream regulator during insulin-stimulated glucose uptake.    3T3-L1 
adipocytes were electroporated with oligonucleotides targeting CaMKIIδ  which is the 
isoform prevalent in non-muscle cells.     After 72 h, cell lysates were collected and 
subjected to SDS-PAGE and immunoblot analysis.   Our results show that there was a 
reduced level of CaMKIIδ  expression in adipocytes electroporated with CaMKIIδ  
siRNA compared to those with the scramble sequence (Figure 13).   It was also observed 
that levels of phosphorylated MLCK were not inhibited upon insulin stimulation in cells 
with CaMKIIδ  siRNA and were similar to those of cells treated with a scramble siRNA 
(Figure 13). 
 
 
 
32 
 
 
Figure 12.  siRNA treatment effectively decreased protein levels of CaMKIIδ.  3T3-
L1 adipocytes were electroporated with siRNA (1 nmole) targeting either CaMKIIδ or a 
scrambled sequence (Scr). After 72 h adipocytes were serum starved for 4 h and then 
either left untreated or stimulated with insulin (100 nM) for 20 min. Whole cell lysates 
were prepared, subjected to SDS-PAGE and then immunoblotted using antibodies against 
either  CaMKIIδ, P-MLCK, or actin.  
 
CaMKIIδ Knockdown Did Not Alter Insulin-stimulated Glucose Uptake 
To investigate if CaMKIIδ plays a role in insulin-stimulated glucose uptake, a 
glucose uptake assay was performed on cells electroporated with a scramble sequence as 
well as cells electroporated with CaMKIIδ siRNA.  As seen in Figure 14 the levels of 
glucose uptake remained constant under basal conditions for both treatments.  Under 
insulin-stimulated conditions there appeared to be relatively no change in glucose uptake 
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which suggests that the CaMKIIδ isoform might not be a factor in insulin-stimulated 
glucose uptake in 3T3-L1 adipocytes.    
 
 
Figure 13.  CaMKIIδ deficient cells have no impact on glucose uptake in insulin-
stimulated cells.  Adipocytes were electroporated with 1 nmole of either CaMKIIδ or a 
scrambled sequence (Scr). Adipocytes were serum starved for 4 h and then either 
untreated (Basal) or stimulated with insulin (100 nM) for 20 min.  Cells were then 
incubated in a solution containing [1-
14
C]-2-deoxy-D-glucose (0.1µCi/well) and 5 mM 
glucose for an additional 10 min.  Cells were lysed and glucose uptake calculated as 
disintegrations per mg protein. 
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CHAPTER IV 
DISCUSSION 
Recently, myosin II has been implicated in GLUT4-mediated glucose uptake in 
adipocytes.   To better understand the mechanism(s) involved in this process, the 
different myosin II isoforms A and B were knocked down using siRNA to allow distinct 
roles of the isoforms to be explored.  While previous studies have used chemical 
inhibition, these inhibitors do not allow for the distinction between the two isoforms and 
the possibility remains that these methods might result in non-specific effects. My results 
are the first to reveal that inhibition of myosin IIA though the use of isoform-specific 
siRNA resulted in impaired insulin-stimulated glucose uptake.  With the subsequent 
decrease of expression of myosin IIA in the cells treated with siRNA targeting myosin 
IIB, it provides evidence that myosin IIB does not have a role in this process since there 
was no further decrease in insulin-stimulated glucose uptake when both myosin IIA and 
IIB were knocked down.   
I next wanted to examine the activation of myosin IIA.  While several kinases are 
known to activate the RLC of myosin II, inhibition studies have shown that it is MLCK 
that is necessary for insulin-stimulated glucose uptake (14).   I hypothesized that without 
MLCK, myosin IIA would not be able to mediate GLUT4-mediated glucose uptake. 
Unfortunately, siRNA treatment did not measurably knockdown expression of MLCK, 
nor were detectable changes observed in insulin-stimulated glucose uptake.   It is 
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probable that a significantly greater decrease in MLCK expression would be necessary to 
impair insulin-stimulated glucose uptake.   A recent study using rat hepatocytes treated 
with siRNA specific for MLCK found that not only was there a 70% reduction in 
expression of MLCK, but that there was also a reduction in cell proliferation (48).  It is 
possible that knockdown of MLCK requires an increased concentration of siRNA or that 
the concentration I used was insufficient to reduce mRNA levels in a significant number 
of adipocytes.    Western blot analysis was performed to verify protein knockdown; 
however we were unable to find a commercial antibody that would detect either the 220-
MLCK or the 130-MLCK in 3T3-L1 adipocytes.  Interestingly, a study found that 
cultured primary epithelial cells down-regulate the expression of the long and short 
isoforms of MLCK such that the 130 MLCK is virtually undetectable and that with 
continued passages only the 220 isoform was detectable (33).    For future studies, it 
would be beneficial to try increasing oligonucleotide concentration and obtaining a more 
sensitive antibody for protein detection.   Due to the speculation for distinct roles of the 
220- and 130-MLCK isoforms, it might also be of interest to determine if adipocytes 
express both isoforms of MLCK and to specifically target the isoforms to distinguish if 
there is redundancy in function.  Initially, my study had not focused on distinct isoform 
functions of MLCK.  Oligonucleotides were obtained that targeted a region that was 
present in both the 220- and the 130-MLCK.  While it would be difficult at this time to 
specifically knockdown the 130-MLCK since this sequence is also present in the 220- 
isoforms, siRNA sequences can be targeted to the additional amino tail region found only 
in the 220-MLCK.   It is this additional amino tail region that is suggested to be a 
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continuous actin binding region for this isoform (34).   In a recent study, the long-MLCK 
colocalized with actin bundles and also did not associate with either non-muscle myosin 
heavy chain IIA (NMHC-IIA) or NMHC-IIB; however the short MLCK appeared to have 
a perinuclear as well as peripheral localization pattern and was found to associate with 
NMHC-IIA (33).   The 130 isoform did not seem to associate with either NMHC-IIB or 
with F-actin filaments (33).   It is possible that the 130-MLCK phosphorylates myosin 
IIA perinuclearly stimulating myosin IIA to translocate to the plasma membrane and the 
cortically located 220-MLCK then phosphorylates myosin IIA triggering actin 
reorganization at the membrane.  Recent studies have noted there is a distinct localization 
pattern for the long and short MLCK isoforms suggesting this redundancy in expression 
might be due to differential roles these isoforms have in cellular processes.    A recent 
study determined that the 220 kDa and 130 kDa MLCK isoforms had particular 
localization patterns in bovine pulmonary arterial epithelial cells, smooth muscle cells, 
and fibroblasts (33).  
While it is well established that insulin signaling activates the PI3K pathway, it is 
also known that insulin signaling stimulates many other transduction pathways. The 
MAPK pathway has also been linked to insulin-stimulated glucose uptake but the 
substrates involved with this pathway still need to be defined (28).   This signaling 
pathway activates the RAS, RAF, MEK cascade of kinases.   A downstream target of 
MEK is the ERK family of proteins.    Recent studies have shown that ERK1 and 2 are 
able to directly phosphorylate MLCK and this activity led to increased phosphorylation 
of the myosin light chain (MLC) (42). Inhibitors of MEK along with siRNA knockdown 
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of ERK1 and 2 have resulted in reduced cell migration in COS-7 cells suggesting a role 
for ERK in cytoskeletal reorganization (42).  Recently, evidence has revealed that ERK1 
and 2 are not interchangeable but actually have distinct roles.  With evidence linking an 
inhibition of ERK2 to reduced levels of insulin-stimulated glucose uptake and GLUT4 
translocation in muscle cells, I hypothesized that it was specifically ERK2 that played a 
role in the metabolic process of glucose uptake (50).   I hypothesized that ERK2 was 
responsible for the phosphorylation of MLCK and that reduced levels of ERK2 in 3T3-
L1 adipocytes would result in impaired glucose uptake by way of reduced MLCK and 
RLC phosphorylation.   My results reveal that with reduced ERK2 protein expression 
insulin-stimulated glucose uptake was impaired by 20% in comparison to control 
(scramble) levels.  Basal levels of glucose uptake remained fairly constant in the cells 
treated with scramble as well as those with siRNA specific to ERK2.    This reduced level 
of ERK2 appears to have resulted in a decrease in MLCK phosphorylation.    For future 
studies, it would be interesting to determine if knockdown of ERK1 would lead to an 
increased level of insulin-stimulated glucose uptake.  It has also been observed that 
localization of these ERK proteins change in response to different cellular processes.  
While I did not perform confocal or immunoprecipitation analysis of ERK1 and 2 for this 
study that could be an approach pursued in the future to determine their cellular 
localization in relation relation to MLCK.   
While a role for ERK2 is becoming evident for insulin-stimulated glucose uptake 
in 3T3-L1 adipocytes, we were interested in determining an upstream regulator of ERK2.    
Studies have indicated a role for CaMKII both in the regulation of MLCK and in the 
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regulation of ERK1 and 2.   While [Ca2+] intracellular have been found to increase upon 
insulin stimulation in the adipocytes, its role in the insulin signal transduction pathway is 
still unclear.   CaMKIIδ  is initially activated by Ca2+ levels but through 
autophosphorylation of its adjacent subunits, the kinase is able to remain activated long 
after intracellular calcium levels have decreased.  It is possible that this allows CaMKII 
to regulate different substrates involved in the insulin signaling pathway.  Recent studies 
have implicated a role for CaMKII in ERK activation.    Studies using endothelial cells 
expressing a constitutively active CaMKII resulted in a significant increase in ERK 
activity (38, 45).   Phosphorylation of ERK in these cells was inhibited by the CaMKII 
inhibitor, KN-62, and the MEK inhibitor U-0126 (38, 45).   It was also shown that ERK 
phosphorylation was inhibited in the absence of activated CaMKII (38, 45).  Other 
studies using CaMKII inhibitors have shown a decrease in phosphorylation of ERK in 
smooth muscle cells and endothelial cells (39, 45).     However, in a recent paper that 
showed chemical inhibition of CaMKII resulted in a decrease in phosphorylated ERK; 
they were not able to find a subsequent reduction in MLC phosphorylation (45).   
In addition to a role in the MAPK pathway, it is also possible that CaMKIIδ  can 
phosphorylate the RLC of myosin II directly or by way of MLCK.   Research exploring 
the unconventional myosin IC (Myo IC) in adipocytes has found that CaMKIIδ  is able to 
phosphorylate Myo IC in vitro and subsequently activate its ATPase activity (43).  It is 
important to note that this paper achieved a 90% reduction in CaMKIIδ expression and 
used a siRNA concentration of 20 nmole per 10 cm plate as opposed to the 2 nmole per 
15 cm plate that we used in this study.  It is possible that this greater reduction of 
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CaMKIIδ protein levels was required to result in an effect on glucose uptake, and the 
slight reduction of protein expression in my study was not sufficient to allow for 
conclusive results.  While siRNA is a great tool for ascertaining gene function, a balance 
between toxicity and non-specific targeting needs to be maintained when determining the 
appropriate concentration of siRNA to use in each experiment.   
CaMKII is a kinase with multiple substrates which may include ERK2 and 
MLCK.    This is also a kinase with four isoforms with most cells expressing at least one 
of these (38).   In this study the delta isoform was targeted as playing a possible role in 
insulin-stimulated glucose uptake due to a high expression of this isoform in adipocytes.  
Recent research has concluded that in a majority of cells the α, γ, and δ isoforms appear 
to have a nuclear localization pattern, while in neural tissue the β isoform co-localizes 
with the cytoskeleton (37).  It would be beneficial to confirm what isoforms are 
expressed in 3T3-L1 adipocytes.  It is possible that while the delta isoform is highly 
expressed in adipocytes; other isoforms are also expressed and have a potential role in 
insulin-stimulated glucose uptake.   It is also possible that these other CaMKII isoforms 
can compensate for the loss of the delta isoform. 
My results revealed that knockdown of the CaMKIIδ  isoform did not inhibit 
insulin-stimulated glucose uptake in 3T3-L1 adipocytes.   While knockdown of ERK2 
had a noticeable decrease in insulin-stimulated glucose uptake, knockdown of CaMKIIδ  
did not significantly impair ERK phosphorylation (data not shown) or MLCK 
phosphorylation suggestive that this isoform of CaMKII does not play a role in insulin-
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stimulated glucose uptake.  The results of our study were able to show that we could 
successfully knockdown myosin IIA and B expression in adipocytes and that a reduction 
in myosin IIA protein levels in 3T3-L1 adipocytes resulted in impaired insulin-stimulated 
glucose uptake.  We were also able to show that MLCK is phosphorylated upon insulin 
stimulation giving further evidence that this kinase is involved in insulin-stimulated 
glucose uptake.  We were also able to show that ERK2 knockdown was achieved and 
resulted in a decrease in insulin-stimulated phosphorylation of MLCK and also impaired 
insulin-stimulated glucose uptake.  We were also able to show we had a slight reduction 
in protein expression of CaMKIIδ which did not have a significant effect on insulin-
stimulated glucose uptake in 3T3-L1 adipocytes.  These are significant findings in 
delineating a pathway involved in insulin-stimulated glucose uptake in adipocytes leading 
the way to future medicinal targets for type II diabetes. 
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APPENDIX A: TABLES 
 
siRNA duplexes ON-TARGET plus Smart POOL 
 
Scramble 
 
Myosin II A 
 
Myosin II B 
 
5’-UGGUUUACAUGUCGACUAA-3’ 
 
5’-GGGCUUAUCUACACCUAUU-3’ 
 
5’-GUAUUAAGUUUGCGAAGGA-3’ 
 
5’-UGGUUUACAUGUUGUGUGA-3’ 
 
5’-UUGUAGAGCUGGUAGAGAA-3’ 
 
5’-GGACAGAGCAAGAUAUUUU-3’ 
 
5’-UGGUUUACAUGUUUUCUGA-3’ 
 
5’-AUAAGAACCUGCCCAUCUA-3’ 
 
5’-GGGCAUCUCUGCUCGCUAU-3’ 
 
5’-UGGUUUACAUGUUUUCCUA-3’ 
 
5’-GCAGACAAGUACCUCUAUG-3’ 
 
5’-GGACUUAUCUAUACUUACU-3’ 
 
 
 
MLCK 
 
 
CaMKIIδ  
 
MAPK1/ Erk2 
 
5’-GGUCUGUCCUCGCCAAGAA-3’ 
 
 
5’-GAUCAAGGCCGGAGCUUAC-3’ 
 
5’-GGAUACAGAUCUUAAAUUG-3’ 
 
5’-UGACGGAGCGGGAGUGUAU-3’ 
 
5’-GCUAGAAUCUGCCGUCUCU-3’ 
 
 
5’-UGAGAGGGCUAAAGUAUAU-3’ 
 
5’-CAGCCGAGCAGAUGGAUUU-3’ 
 
5’-CGACGAGUAUCAGCUCUUU-3’ 
 
5’-ACAAGAGGAUUGAAGUUGA-3’ 
 
5’-CGACUAGGAUCUGGGAAAU-3’ 
 
5’-GAAGCGGGAUGCCAAAGAC-3’ 
 
5’-UAUACCAAGUCCAUUGAUA-3’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
